Effect of Tongluo Shenggu Prescription on ARCO Stage Ⅱ non-traumatic femoral head necrosis: A prospective study

• 作者: Chao Lu Chen Yang Gao-Kui Zhang Wen-Xing Yu Xue-Chao Yuan Yang-Quan Hao
• 来源期刊: 海南医科大学学报（英文版）
• 年，卷（期）: 2020,（24）
• 所属期刊栏目: Original article
• 页码范围: 23-27
• 页数: 5页
• 语种: 英文

摘要

Objective: To observe the clinical results and therapeutic characteristics of Tongluo Shenggu Decoction in the treatment of ARCO Ⅱ non-traumatic femoral head necrosis. Methods: 120 patients with ARCO Ⅱ non-traumatic femoral head necrosis from January 2016 to January 2017 were studied by prospective matched and controlled design. 60 cases in the treatment group were treated with Tongluo Shenggu Formula. The control group (60 cases) received high energy extracorporeal shock wave therapy. The imaging stability rate, Harris score and SF-36 score were used as clinical efficacy indicators, followed up for 24 months, and the follow-up results were statistically analyzed. Results: Among the 120 patients, 5 fell off and the rest were followed up. The imaging stability rate is heavy. The imaging stability rate of the patients in the treatment group is 78.95％, while that in the control group is 72.41％. The two groups have the same stability rate (P > 0.05). In Harris score, the Harris score of the patients in the treatment group was 92.678.45 points, significantly higher than that of the control group (80.3924.65 points), the difference was statistically significant (p < 0.05), and the pain degree, joint function and joint deformity score of the treatment group were better than those of the control group (p < 0.05). In the SF-36 score, the scores of physiological function, physiological function, physical pain, overall health, social function and emotional function in the treatment group were significantly higher than those in the control group, the difference was statistically significant (p < 0.05). the incidence of adverse events in the treatment period of the two groups was lower and the patients could relieve themselves in the later stage. Conclusion: Tongluo Shenggu prescription has definite curative effect in treating ARCO Ⅱ non-traumatic femoral head necrosis, especially in improving hip joint function, relieving hip joint pain and improving quality of life.To observe the clinical results and therapeutic characteristics of Tongluo Shenggu Decoction in the treatment of ARCO Ⅱ non-traumatic femoral head necrosis. Methods: 120 patients with ARCO Ⅱ non-traumatic femoral head necrosis from January 2016 to January 2017 were studied by prospective matched and controlled design. 60 cases in the treatment group were treated with Tongluo Shenggu Formula. The control group (60 cases) received high energy extracorporeal shock wave therapy. The imaging stability rate, Harris score and SF-36 score were used as clinical efficacy indicators, followed up for 24 months, and the follow-up results were statistically analyzed. Results: Among the 120 patients, 5 fell off and the rest were followed up. The imaging stability rate is heavy. The imaging stability rate of the patients in the treatment group is 78.95％, while that in the control group is 72.41％. The two groups have the same stability rate (P > 0.05). In Harris score, the Harris score of the patients in the treatment group was 92.678.45 points, significantly higher than that of the control group (80.3924.65 points), the difference was statistically significant (p < 0.05), and the pain degree, joint function and joint deformity score of the treatment group were better than those of the control group (p < 0.05). In the SF-36 score, the scores of physiological function, physiological function, physical pain, overall health, social function and emotional function in the treatment group were significantly higher than those in the control group, the difference was statistically significant (p < 0.05). the incidence of adverse events in the treatment period of the two groups was lower and the patients could relieve themselves in the later stage. Conclusion: Tongluo Shenggu prescription has definite curative effect in treating ARCO Ⅱ non-traumatic femoral head necrosis, especially in improving hip joint function, relieving hip joint pain and improving quality of life.